Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer

Featuring an interview with Dr Michiel van der Heijden, including the following topics: Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00) Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15) Activity of anti-PD1/PD-L1 and anti-CTLA4 combinations for patients with bladder cancer; role of circulating and urinary tumor DNA in urothelial carcinoma (6:40) Case: A 61-year-old woman with metastatic urothelial bladder cancer (mUBC) treated with first-line enfortumab vedotin and pembrolizumab (19:34) Case: A 63-year-old man with extensive mUBC whose disease progresses on avelumab maintenance receives enfortumab vedotin (25:54) CME information and select publications